|
|
|
|
|
 |
|
|
Overview
LunGuard is dedicated to the development of advanced enteral feeding equipment. The Company is developing a unique and proprietary device for the enteral feeding market. LunGuard’s product is a Peristaltic Feeding Tube (PFT) that is capable of managing reflux, preventing pulmonary aspiration and is expected to significantly lower the occurrence of Ventilator Associated Pneumonia (VAP) in ventilated patients. The company was founded in 2009, under the CS incubator program and has completed a functional prototype in preparation for human clinical testing. Clinical trials initiation is expected on Q3/2010 while CE mark on Q4/2011.
The system is composed of two main components: the bedside CMU (Control and Monitoring Unit) and a unique disposable PFT that is furnished with at least three balloons that mimic the esophagus peristaltic wave and is designed to prevent reflux induced aspiration while at the same time allow liquids (such as saliva) to flow down the esophagus. Other than its unique reflux-management functionalities, the PFT operates just as any regular NG tube, fulfilling the same functions, and is inserted and handled in precisely the same way.
|
|
|
The need
Enteral feeding refers to the delivery of liquid feedings through a tube. Enteral feeding, are used in patients who have a functioning gastrointestinal tracts, but are unable to orally ingest adequate nutrients to meet their metabolic needs, due to gastrointestinal disorders, neuromuscular disorders, such as ALS, muscular dystrophy, spinal cord defects, or damage to the central nervous system, cardiopulmonary disorders and other conditions of hyper metabolism such as burns and cancer. Enteral feeding occurs in various hospital settings to provide nutritional stability to premature infants, as well as in the ICU. Over the last twenty years, demand for enteral nutrition has risen rapidly.
Enteral feeding is the primary choice for nutritional supplementation; however, gastroesophageal reflux combined with aggressive enteral feeding may increase his risk of aspiration or vomiting. The PFT aims to dramatically reduce gastric reflux toward the respiratory system and significantly reduces aspiration episodes. Such aspirations are associated with increased episodes of ventilator associated pneumonia VAP in the adult ICU and very preterm new born and are problematic for non elective OR procedures, ALS patients and other indications. VAP episodes reduction in the adult ICU and preterm newborns may significantly reduce length of stay and mortality events.
|
|
|
|
 |
|
|
The vision
Early feeding is one of the significant accelerators related to patient recovery yet there are associated side effects due to intensive nutrition administration directly ...
|
|
|
CMU
The CMU controls the PFT’s balloons activity, inflating and deflating them, keeping the correct (ongoing balance between efficacy & safety) amount of pressure at all time...
|
|
|
The Team
Mr. Pintel leads the company since December 2008 as an incubator company under Maayan ventures, Omer. In the last two years he was involved in implanted CGM (Continuous G...
|
|
|
|
